Emerging from stealth in late 2022, Palo Alto–based biopharma startup OrsoBio announced four development programs targeting severe metabolic disorders. The CEO and founder, Dr. Mani Subramanian and chief medical officer and head of development Dr. Rob Myers formerly worked at Gilead. Founded in 2020 with a quest to “try to modulate energy metabolism in severe…